Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
1. An isolated antibody that specifically binds vascular endothelial growth factor (VEGF), wherein the antibody comprises the following six hypervariable regions (HVRs):
(a) an HVR-H1 comprising the amino acid sequence of DYWIH (SEQ ID NO: 1);
(b) an HVR-H2 comprising the amino acid sequence of GX 1 TPX 2 GGX 3 X 4 X 5 YX 6 DSVX 7 X 8 (SEQ ID NO: 2), wherein X 1 is Ile or His, X 2 is Ala or Arg, X 3 is Tyr or Lys, X 4 is Thr or Glu, X 5 is Arg, Tyr, Gln, or Glu, X 6 is Ala or Glu, X 7 is Lys or Glu, and X 8 is Gly or Glu;
(c) an HVR-H3 comprising the amino acid sequence of FVFFLPYAMDY (SEQ ID NO: 3);
(d) an HVR-L1 comprising the amino acid sequence of RASQX 1 VSTAVA (SEQ ID NO: 4), wherein X 1 is Asp or Arg;
(e) an HVR-L2 comprising the amino acid sequence of X 1 ASFLYS (SEQ ID NO: 5), wherein X 1 is Ser or Met; and
(f) an HVR-L3 comprising the amino acid sequence of X 1 QGYGX 2 PFT (SEQ ID NO: 6), wherein X 1 is Gln, Asn, or Thr and X 2 is Ala, Gln, or Arg.
2. The antibody of claim 1 , wherein the antibody comprises the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of DYWIH (SEQ ID NO: 1);
(b) an HVR-H2 comprising the amino acid sequence of GITPAGGYTRYADSVKG (SEQ ID NO: 7), GITPAGGYEYYADSVKG (SEQ ID NO: 21), or GITPAGGYEYYADSVEG (SEQ ID NO: 22);
(c) an HVR-H3 comprising the amino acid sequence of FVFFLPYAMDY (SEQ ID NO: 3);
(d) an HVR-L1 comprising the amino acid sequence of RASQDVSTAVA (SEQ ID NO: 8);
(e) an HVR-L2 comprising the amino acid sequence of SASFLYS (SEQ ID NO: 9); and
(f) an HVR-L3 comprising the amino acid sequence of QQGYGAPFT (SEQ ID NO: 10) or QQGYGNPFT (SEQ ID NO: 23).
3. The antibody of claim 2 , wherein the antibody comprises the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of DYWIH (SEQ ID NO: 1);
(b) an HVR-H2 comprising the amino acid sequence of GITPAGGYTRYADSVKG (SEQ ID NO: 7);
(c) an HVR-H3 comprising the amino acid sequence of FVFFLPYAMDY (SEQ ID NO: 3);
(d) an HVR-L1 comprising the amino acid sequence of RASQDVSTAVA (SEQ ID NO: 8);
(e) an HVR-L2 comprising the amino acid sequence of SASFLYS (SEQ ID NO: 9); and
(f) an HVR-L3 comprising the amino acid sequence of QQGYGAPFT (SEQ ID NO: 10).
4. The antibody of claim 3 , wherein the antibody further comprises the following heavy chain variable (VH) domain framework regions (FRs):
(a) an FR-H1 comprising the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTIS (SEQ ID NO: 13);
(b) an FR-H2 comprising the amino acid sequence of WVRQAPGKGLEWVA (SEQ ID NO: 14);
(c) an FR-H3 comprising the amino acid sequence of RFTISADTSKNTAYLQMRSLRAEDTAVYYCAR (SEQ ID NO: 15); and
(d) an FR-H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 16).
5. The antibody of claim 4 , wherein the antibody further comprises the following light chain variable (VL) domain FRs:
(a) an FR-L1 comprising the amino acid sequence of DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 17);
(b) an FR-L2 comprising the amino acid sequence of WYQQKPGKAPKLLIY (SEQ ID NO: 18);
(c) an FR-L3 comprising the amino acid sequence of GVPSRFSGSGSGTDFTLTISSLQPEDAATYYC (SEQ ID NO: 19); and
(d) an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID NO: 20).
6. The antibody of claim 1 , wherein the antibody is capable of inhibiting the binding of VEGF to a VEGF receptor.
7. The antibody of claim 6 , wherein the VEGF receptor is VEGF receptor 1 (Flt-1) or VEGF receptor 2 (KDR).
8. The antibody of claim 1 , wherein the antibody binds human VEGF (hVEGF) with a Kd of about 2 nM or lower; has a melting temperature (Tm) of greater than about 83.5° C.; and/or has an isoelectric point (pI) of lower than 8.
9. The antibody of claim 1 , wherein the antibody is monoclonal, human, humanized, or chimeric.
10. The antibody of claim 1 , wherein the antibody is an antibody fragment that binds VEGF.
11. The antibody of claim 10 , wherein the antibody fragment is selected from the group consisting of Fab, Fab-C, Fab′-SH, Fv, scFv, and (Fab′) 2 fragments.
12. The antibody of claim 1 , wherein the antibody is a monospecific antibody.
13. The antibody of claim 1 , wherein the antibody is a multispecific antibody.
14. The antibody of claim 13 , wherein the multispecific antibody is a bispecific antibody.
15. An antibody conjugate comprising (i) the antibody of claim 1 and (ii) a hydrophilic polymer covalently attached to the antibody.
16. The antibody conjugate of claim 15 , wherein the hydrophilic polymer is a hyaluronic acid (HA) polymer or a polyethylene glycol (PEG) polymer.
17. The antibody conjugate of claim 16 , wherein the hydrophilic polymer is an HA polymer.
18. The antibody conjugate of claim 15 , wherein the antibody is an antibody fragment that binds VEGF.
19. The antibody conjugate of claim 18 , wherein the antibody fragment is selected from the group consisting of Fab, Fab-C, Fab′, Fab′-SH, Fv, scFv, and (Fab′) 2 fragments.
20. The antibody conjugate of claim 15 , wherein the antibody conjugate has a hydrodynamic radius between about 10 nm and about 60 nm.
21. The antibody conjugate of claim 15 , wherein the antibody conjugate has an ocular half-life that is increased relative to a reference antibody that is not covalently attached to the hydrophilic polymer.
22. The antibody conjugate of claim 15 , wherein the antibody is covalently attached to the polymer by a reversible prodrug linker.
23. The antibody conjugate of claim 22 , wherein the polymer is a hydrogel.
24. The antibody conjugate of claim 23 , wherein the hydrogel is a PEG-based hydrogel.
25. A fusion protein comprising the antibody of claim 1 covalently attached to an HA binding domain.
26. The antibody of claim 1 , wherein the antibody further comprises (a) a VH domain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 11, 40, or 42; (b) a VL domain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 12, 41, or 46; or (c) a VH domain as in (a) and a VL domain as in (b).
27. A pharmaceutical composition comprising the antibody of claim 1 .
28. A method of reducing or inhibiting angiogenesis in a subject having a disorder associated with pathological angiogenesis, comprising administering to the subject an effective amount of the antibody of claim 1 , thereby reducing or inhibiting angiogenesis in the subject.
29. A method for treating a disorder associated with pathological angiogenesis, the method comprising administering an effective amount of the antibody of claim 1 to a subject in need of such treatment.
30. The method of claim 29 , wherein the disorder associated with pathological angiogenesis is an ocular disorder or a cell proliferative disorder.
31. The method of claim 30 , wherein the ocular disorder is selected from the group consisting of AMD, macular degeneration, macular edema, DME (including focal, non-center DME and diffuse, center-involved DME), retinopathy, DR (including PDR, NPDR, and high-altitude DR), other ischemia-related retinopathies, ROP, RVO (including CRVO and BRVO forms), CNV (including myopic CNV), corneal neovascularization, a disease associated with corneal neovascularization, retinal neovascularization, a disease associated with retinal/choroidal neovascularization, pathologic myopia, von Hippel-Lindau disease, histoplasmosis of the eye, FEVR, Coats' disease, Norrie Disease, OPPG, subconjunctival hemorrhage, rubeosis, ocular neovascular disease, neovascular glaucoma, RP, hypertensive retinopathy, retinal angiomatous proliferation, macular telangiectasia, iris neovascularization, intraocular neovascularization, retinal degeneration, CME, vasculitis, papilloedema, retinitis, conjunctivitis (including infectious conjunctivitis and non-infectious (e.g., allergic) conjunctivitis), Leber congenital amaurosis, uveitis (including infectious and non-infectious uveitis), choroiditis, ocular histoplasmosis, blepharitis, dry eye, traumatic eye injury, and Sjögren's disease.
32. The method of claim 31 , wherein the ocular disorder is selected from the group consisting of AMD, DME, DR, and RVO.
33. The method of claim 29 , further comprising administering to the subject an effective amount of a second agent, wherein the second agent is selected from the group consisting of another antibody, a chemotherapeutic agent, a cytotoxic agent, an anti-angiogenic agent, an immunosuppressive agent, a prodrug, a cytokine, a cytokine antagonist, cytotoxic radiotherapy, a corticosteroid, an anti-emetic, a cancer vaccine, an analgesic, a growth-inhibitory agent, and a compound that binds to a second biological molecule.
34. The method of claim 33 , wherein the second biological molecule is selected from the group consisting of IL-1β; IL-6; IL-6R; IL-13; IL-13R; PDGF; angiopoietin; angiopoietin 2; Tie2; S1 P; integrins αvβ3, αvβ5, and α5β1; betacellulin; apelin/APJ; erythropoietin; complement factor D; TNFα; HtrA1; a VEGF receptor; ST-2 receptor.
35. A method of reducing or inhibiting angiogenesis in a subject having a disorder associated with pathological angiogenesis, comprising administering to the subject an effective amount of the antibody conjugate of claim 15 , thereby reducing or inhibiting angiogenesis in the subject.
36. A method for treating a disorder associated with pathological angiogenesis, the method comprising administering an effective amount of the antibody conjugate of claim 15 to a subject in need of such treatment.
37. The method of claim 36 , wherein the disorder associated with pathological angiogenesis is an ocular disorder.
38. The method of claim 37 , wherein the ocular disorder is selected from the group consisting of AMD, macular degeneration, macular edema, DME (including focal, non-center DME and diffuse, center-involved DME), retinopathy, DR (including PDR, NPDR, and high-altitude DR), other ischemia-related retinopathies, ROP, RVO (including CRVO and BRVO forms), CNV (including myopic CNV), corneal neovascularization, a disease associated with corneal neovascularization, retinal neovascularization, a disease associated with retinal/choroidal neovascularization, pathologic myopia, von Hippel-Lindau disease, histoplasmosis of the eye, FEVR, Coats' disease, Norrie Disease, OPPG, subconjunctival hemorrhage, rubeosis, ocular neovascular disease, neovascular glaucoma, RP, hypertensive retinopathy, retinal angiomatous proliferation, macular telangiectasia, iris neovascularization, intraocular neovascularization, retinal degeneration, CME, vasculitis, papilloedema, retinitis, conjunctivitis (including infectious conjunctivitis and non-infectious (e.g., allergic) conjunctivitis), Leber congenital amaurosis, uveitis (including infectious and non-infectious uveitis), choroiditis, ocular histoplasmosis, blepharitis, dry eye, traumatic eye injury, and Sjögren's disease.
39. The method of claim 38 , wherein the ocular disorder is selected from the group consisting of AMD, DME, DR, and RVO.
40. A pharmaceutical composition comprising the antibody conjugate of claim 15 .
41. An isolated antibody that specifically binds VEGF, wherein the antibody comprises (a) a VH domain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 11; (b) a VL domain comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 12; or (c) a VH domain as in (a) and a VL domain as in (b).
42. The antibody of claim 41 , wherein the VH domain further comprises the following FRs:
(a) an FR-H1 comprising the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTIS (SEQ ID NO: 13);
(b) an FR-H2 comprising the amino acid sequence of WVRQAPGKGLEWVA (SEQ ID NO: 14) or WVRQEPGKGLEWVA (SEQ ID NO: 39);
(c) an FR-H3 comprising the amino acid sequence of RFTISADTSKNTAYLQMRSLRAEDTAVYYCAR (SEQ ID NO: 15); and
(d) an FR-H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 16).
43. The antibody of claim 42 , wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 11.
44. The antibody of claim 41 , wherein the VL domain further comprises the following FRs:
(a) an FR-L1 comprising the amino acid sequence of DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 17) or DIQMTQSPSSLSASVGDRVTIDC (SEQ ID NO: 45);
(b) an FR-L2 comprising the amino acid sequence of WYQQKPGKAPKLLIY (SEQ ID NO: 18);
(c) an FR-L3 comprising the amino acid sequence of GVPSRFSGSGSGTDFTLTISSLQPEDAATYYC (SEQ ID NO: 19), GVPSRFSGSGSGTDFTLTISSLQPEDSATYYC (SEQ ID NO: 44), or GVPSRFSGSGSGTDFTLTISSLQPEDVATYYC (SEQ ID NO: 54); and
(d) an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID NO: 20) or FGQGTKVEVK (SEQ ID NO: 55).
45. The antibody of claim 44 , wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 12.
46. An isolated antibody that specifically binds VEGF, wherein the antibody comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 11 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 12.
47. An isolated antibody that specifically binds VEGF, wherein the antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 48 and (b) a light chain comprising the amino acid sequence of SEQ ID NO: 50.
48. An isolated antibody that specifically binds VEGF, wherein the antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 49 and (b) a light chain comprising the amino acid sequence of SEQ ID NO: 50.